Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2023-05-22 6-K DIRECTORATE CHANGE View Document
2023-05-17 6-K TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER View Document
2023-05-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-09 6-K FARXIGA EXTENDED IN THE US FOR HEART FAILURE View Document
2023-05-02 6-K TOTAL VOTING RIGHTS View Document
2023-05-02 6-K ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER View Document
2023-05-02 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-27 6-K 1ST QUARTER RESULTS View Document
2023-04-27 6-K RESULT OF AGM View Document
2023-04-27 6-K FORM 6-K View Document
2023-04-27 6-K BOARD COMMITTEE CHANGES View Document
2023-04-26 6-K DIRECTOR DECLARATION View Document
2023-04-11 6-K UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI View Document
2023-04-05 6-K LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER View Document
2023-04-03 6-K TOTAL VOTING RIGHTS View Document
2023-04-03 6-K ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL View Document
2023-03-30 6-K ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 View Document
2023-03-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-22 6-K FORM 6-K View Document
2023-03-22 6-K NOTICE OF AGM View Document
2023-03-15 CERT View Document
2023-03-13 8-A12B 8-A12B View Document
2023-03-09 6-K IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER View Document
2023-03-08 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-08 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-06 6-K ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS View Document
2023-03-03 6-K FORM 6-K View Document
2023-03-02 424B2 424B2 View Document
2023-03-01 6-K TOTAL VOTING RIGHTS View Document
2023-03-01 6-K ASTRAZENECA PRICES A $2.25BN BOND OFFERING View Document
2023-03-01 FWP FWP View Document
2023-02-28 424B2 424B2 View Document
2023-02-24 6-K ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING View Document
2023-02-24 6-K ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET View Document
2023-02-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-24 SC TO-T/A SC TO-T/A View Document
2023-02-23 6-K ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 View Document
2023-02-23 SC TO-T/A SC TO-T View Document
2023-02-22 6-K FILING OF FORM 20-F WITH SEC View Document
2023-02-21 6-K FORM 6-K View Document
2023-02-21 IRANNOTICE IRANNOTICE View Document
2023-02-21 20-F FORM 20-F View Document
2023-02-21 6-K ANNUAL FINANCIAL REPORT View Document
2023-02-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-10 SC 13G/A SC 13G/A View Document
2023-02-10 SC 13G/A SC 13G/A View Document
2023-02-09 6-K FINAL RESULTS View Document
2023-02-03 SC TO-T/A SC TO-T/A View Document
2023-02-01 6-K TOTAL VOTING RIGHTS View Document
2023-01-26 6-K UPDATE ON EVUSHELD US EUA View Document
2023-01-24 SC 13G/A View Document
2023-01-23 SC TO-T SC TO-T View Document
2023-01-17 6-K ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED View Document
2023-01-11 6-K AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA View Document
2023-01-09 SC TO-C SC TO-C View Document
2023-01-09 6-K ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET View Document
2023-01-03 6-K TOTAL VOTING RIGHTS View Document
2022-12-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-28 6-K CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL View Document
2022-12-28 6-K IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS View Document
2022-12-21 6-K IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER View Document
2022-12-21 6-K LYNPARZA APPROVED IN EU FOR PROSTATE CANCER View Document
2022-12-19 6-K ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME View Document
2022-12-19 6-K ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD View Document
2022-12-19 6-K IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT View Document
2022-12-19 6-K UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL View Document
2022-12-19 6-K FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF View Document
2022-12-15 6-K UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA View Document
2022-12-08 6-K CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER View Document
2022-12-01 6-K TOTAL VOTING RIGHTS View Document
2022-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2022-11-30 6-K ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE View Document
2022-11-29 6-K ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS View Document
2022-11-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-11-14 6-K ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC View Document
2022-11-14 6-K IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC View Document
2022-11-14 6-K LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC View Document
2022-11-14 6-K IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER View Document
2022-11-10 6-K YTD AND Q3 2022 RESULTS View Document
2022-11-09 6-K FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA View Document
2022-11-04 6-K BEYFORTUS (NIRSEVIMAB) APPROVED IN EU View Document
2022-11-01 6-K TOTAL VOTING RIGHTS View Document
2022-10-26 6-K CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS View Document
2022-10-25 6-K UPDATE ON MESSINA PHASE III TRIAL View Document
2022-10-24 6-K IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER View Document
2022-10-03 6-K TOTAL VOTING RIGHTS View Document
2022-09-30 6-K BOARD COMMITTEE CHANGES View Document
2022-09-27 6-K KOSELUGO APPROVED IN JAPAN FOR NF1 View Document
2022-09-27 6-K TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA View Document
2022-09-23 6-K ULTOMIRIS APPROVED IN EU FOR GMG View Document
2022-09-22 6-K LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER View Document
2022-09-21 6-K TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA View Document
2022-09-20 6-K EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT View Document
2022-09-16 6-K DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT View Document
2022-09-16 6-K NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP View Document
2022-09-16 6-K EVUSHELD POSITIVE CHMP OPINION IN EU View Document
2022-09-06 6-K FORXIGA APPROVED IN CHINA FOR CKD View Document
2022-09-06 6-K IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER View Document
2022-09-01 6-K TOTAL VOTING RIGHTS View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299